Moderna

COVID-19 Vaccine Outcomes in Dermatomyositis Patients

A recent study evaluated the safety and efficacy of the Moderna, Pfizer, and Johnson & Johnson COVID-19 vaccines in dermatomyositis (DM) patients compared to non-DM patients at 1, 30, and 60 days post-vaccination. At 60 days post-vaccination, the DM group was observed to be at greater risk for adverse events of special interest compared to controls, albeit very small (absolute risk was .6%). No differences were observed for breakthrough infection or all-cause hospitalization at 60 days post-vaccination.

Read More »

Antibody Levels in Immunocompromised Patients after Second Dose of mRNA Vaccine

Researchers at Johns Hopkins tested antibody levels in patients at 1, 3, and 6 months after the second dose of an mRNA vaccine. Overall, 96% of patients had positive antibody titers 6 months after the second dose of an mRNA vaccine. Antibody responses decreased from 1 to 6 months, but remained above the threshold for “predicted neutralizing capacity” in the majority of patients.

Read More »

Results of Com-Cov Mix-and-Match Vaccine Study

The Com-Cov2 study tested the efficacy and safety of mix-and-matching COVID-19 vaccines, including Pfizer, AstraZeneca, Moderna and Novavax. Moderna or Novavax vaccines were administered 8-12 weeks after a first dose of the Pfizer or AstraZeneca vaccine, measuring for IgG antibodies at 28 days after the second dose.

Read More »
Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.